01Approach to the Critical Patient/attcp61

Immediate resuscitation

›Airway and oxygenation

›High-flow supplemental oxygen via non-rebreather mask

›Does not correct methemoglobinemia but maximizes dissolved O2

›Target SpO2 as measured by co-oximetry, not pulse oximetry

›Airway compromise triggers

›GCS <8 or inability to protect airway

›Proceed to rapid sequence intubation

›Recognize pulse oximetry limitation

›Pulse oximetry plateaus ~82-87% regardless of true saturation

›Saturation gap between SpO2 and co-oximetry confirms methemoglobinemia

›Circulation stabilization

›Hypotension management

›IV crystalloid bolus 500-1000 mL

›Passive leg raise and Trendelenburg positioning

›Avoid epinephrine for nitrate-induced hypotension

›Vasopressor if refractory

›Norepinephrine 0.1-0.3 mcg/kg/min, titrate to MAP >65 mmHg

›Phenylephrine as alternative for tachycardia without hyperdynamic state

›IV access and continuous cardiac monitoring

›Two large-bore peripheral IVs

›12-lead ECG for ischemia and arrhythmia

›Antidote threshold triggers

›Methylene blue indications

›MetHb level >=30% regardless of symptoms

›MetHb level >=20% with symptomatic patients

›Cyanosis unresponsive to oxygen at any MetHb level

›Methylene blue 1 mg/kg IV over 5-30 minutes

02History/hx75

Exposure history

›Source and route of nitrate exposure

›Intentional ingestion

›Sodium nitrite increasingly purchased online for self-harm

›Suicidal ideation and intent

›Pharmaceutical overdose

›Nitroglycerin, isosorbide dinitrate, isosorbide mononitrate

›Sodium nitroprusside infusion cumulative dose

›Occupational or environmental

›Agricultural fertilizer handlers

›Industrial chemical workers

›Private well water in rural agricultural areas

›Dietary

›Contaminated vegetable broth or high-nitrate vegetables

›Processed meats with nitrite preservatives

›Well water mixed with infant formula

›Recreational

›Amyl nitrite or isobutyl nitrite poppers

›Timing and quantity

›Time of ingestion or exposure

›Onset within minutes for inhalation and IV exposure

›Onset delayed 1-4 hours for oral nitrate ingestion via gut bacterial conversion

›Amount ingested and formulation

›Concentration of solution if applicable

›Co-ingestants

Symptom progression

›Classic symptom sequence

›Early phase

03Physical Exam/exam45

Vital signs

›Vital sign pattern

›Tachycardia early

›Compensatory response to functional anemia

›Bradycardia in severe/late organic nitrate overdose

›Hypotension

›Nitric oxide-mediated vasodilation and venodilation

›MAP <65 mmHg indicates hemodynamic compromise

›Tachypnea progressing to bradypnea

›Central respiratory depression in severe toxicity

›Clear lungs despite apparent hypoxia

Skin and mucous membranes

›Cyanosis characteristics

›Chocolate-brown or gray-blue discoloration

›Disproportionate to respiratory status

›Present in mucous membranes and nail beds

›Blood color assessment

›Chocolate-brown venous blood on venipuncture

›Does not turn red on exposure to air

›Pathognomonic for methemoglobinemia

›Initial flushing phase

›Diaphoresis with early vasodilation

›Transitioning to cold clammy skin as shock develops

Neurologic exam

›Mental status

›Lethargy and confusion

›Correlates with MetHb level typically >30%

›Obtundation suggests MetHb >45%

04Differential Diagnosis/ddx46

Life-threatening mimics

›Cyanide poisoning

›ICD-10 T65.0

›Concurrent in sodium nitroprusside toxicity

›Lactic acidosis, AMS, seizures, cherry-red skin late

›Responds to hydroxocobalamin or sodium thiosulfate

›Carbon monoxide poisoning

›ICD-10 T58

›SpO2 falsely normal on pulse oximetry

›Co-oximetry differentiates with elevated COHb

›History of exposure to combustion products

›Sulfhemoglobinemia

›ICD-10 D74.8

›Similar cyanosis refractory to oxygen

›Does NOT respond to methylene blue

›Co-oximetry may misidentify as MetHb

›Associated with sulfonamides, dapsone, hydrogen sulfide

Cardiac and vascular causes

›Cardiogenic shock

›ICD-10 R57.0

›Crackles, elevated JVP, S3, BNP elevation

›Troponin, BNP, ECG differentiate

›Pulmonary embolism

›ICD-10 I26.99

›Hypoxia with SpO2 improving on supplemental O2

›D-dimer, CTA chest differentiate

›Aortic dissection

›ICD-10 I71.0

05Laboratory Tests/lt47

Co-oximetry

›ABG with co-oximetry

›Gold standard for methemoglobin diagnosis

›Directly measures MetHb fraction

›Standard pulse oximetry cannot differentiate MetHb from deoxyhemoglobin

›Interpretation by MetHb level

›<10%: usually asymptomatic

›10-20%: cyanosis, mild symptoms

›20-30%: headache, dyspnea, fatigue, anxiety, tachycardia

›30-50%: confusion, chest pain, syncope

›>50%: seizures, coma, dysrhythmias

›>70%: death

›PaO2 typically normal despite clinical cyanosis

›Saturation gap is diagnostic

›PaO2 normal confirms functional rather than respiratory hypoxia

Metabolic and electrolytes

›Basic metabolic panel

›Metabolic acidosis assessment

›Lactic acidosis suggests concurrent cyanide toxicity

›Anion gap elevation with nitroprusside-associated cyanide

›Renal function

›Guides methylene blue dosing and hydration

›Creatinine and BUN baseline

›Glucose

›Hypoglycemia as complicating cause of altered mental status

Hematologic tests

›Complete blood count

›Hemolytic anemia screen

06Diagnostic Tests/dt59

Scoring Systems

›MetHb severity classification

›Mild: MetHb 10-20%

›Cyanosis without significant symptoms

›Observation and oxygen

›Moderate: MetHb 20-30%

›Headache, dyspnea, fatigue

›Methylene blue if symptomatic

›Severe: MetHb 30-50%

›Confusion, syncope, chest pain

›Methylene blue regardless of symptoms

›Life-threatening: MetHb >50%

›Seizures, coma, cardiovascular collapse

›Emergent methylene blue and ICU care

›Poison severity score for methemoglobinemia

›Clinical severity context

›Comorbidities lower the symptomatic threshold at any MetHb level

›Cardiopulmonary disease: symptoms at MetHb as low as 10%

›Anemia: symptoms earlier due to reduced oxygen carrying reserve

MRI

›MRI head indications

›Altered mental status persisting after MetHb correction

›Anoxic brain injury assessment

›Posterior reversible encephalopathy syndrome consideration

›Diffusion-weighted imaging

›Watershed zone ischemia from prolonged cerebral hypoxia

›Basal ganglia injury pattern in severe toxicity

›MRI brain limitations

07Disposition/dispo42

ICU admission

›ICU indications

›MetHb level >=30%

›Methylene blue required

›Serial MetHb monitoring every 30-60 minutes

›Hemodynamic instability

›Hypotension requiring vasopressors

›Persistent tachycardia despite treatment

›Neurologic compromise

›Altered mental status or seizures

›GCS <13

›Cardiac arrhythmias

›Heart block

›ST-segment changes

›Concurrent cyanide toxicity

›Sodium nitroprusside infusion related

›Lactic acidosis with AMS

›Rebound methemoglobinemia risk

›Long-acting agents: dapsone, large nitrate ingestions

Monitored bed admission

›Step-down or observation unit

›MetHb 10-30% with symptoms

›Single methylene blue dose given

›Clinical response confirmed

›Requires methylene blue with subsequent resolution

›Monitor for rebound 4-8 hours post-treatment

›Particularly with long-acting oxidant drug ingestion

08Treatment/t70

Oxygen therapy

›High-flow supplemental oxygen

›Non-rebreather mask at 15 L/min

›Maximizes dissolved plasma oxygen

›Does not reduce MetHb fraction directly

›Maintains partial pressure of O2 while antidote acts

›Intubation for airway compromise

›Rapid sequence intubation

›Post-intubation ventilation strategy

›FiO2 1.0 initially

›Titrate FiO2 downward as MetHb normalizes

Antidotal therapy

›Methylene blue

›Mechanism

›Reduces MetHb to functional hemoglobin via NADPH methemoglobin reductase

›Requires intact G6PD pathway

›Dosing

›1 mg/kg IV over 5-30 minutes

›Repeat 1 mg/kg once if MetHb remains >30% after 30-60 minutes

›Maximum 2 doses before alternative therapy

›Monitoring post-administration

›Co-oximetry 30-60 minutes after dose

›CBC for hemolysis after each dose

›Repeat MetHb 4-8 hours for rebound with long-acting agents

›Contraindications and cautions

›G6PD deficiency: ineffective and causes hemolysis

›Serotonin syndrome risk: use with caution in patients on serotonergic drugs

›May cause falsely elevated SpO2 on pulse oximetry transiently

09Special Populations/sp71

Pregnancy

›Physiologic considerations

›Increased plasma volume and hemodilution

›Baseline lower hemoglobin reduces oxygen reserve

›Fetal hemoglobin more susceptible to oxidation than adult hemoglobin

›Placental transfer of nitrites and methylene blue

›Methylene blue crosses placenta

›Fetal methemoglobinemia may require additional intervention

›Treatment modifications

›Methylene blue in pregnancy

›Use when benefit outweighs risk

›Life-threatening maternal methemoglobinemia is an absolute indication

›Fetal monitoring required post-administration

›Category X in some classifications but benefit outweighs risk in toxicity

›Positioning

›Left lateral decubitus to reduce aortocaval compression

›Relevant during fluid resuscitation and monitoring

›Obstetric consultation

›Fetal heart rate monitoring for viable gestational age

›Neonatology alert for periviable and viable pregnancies

›Dietary nitrate risk in pregnancy

›Elevated nitrate exposure associated with fetal methemoglobinemia

›Well water contamination risk persists in pregnancy

›Counsel on water source safety

Geriatric

›Age-related susceptibility

›Reduced cardiac reserve

›Lower MetHb threshold for hemodynamic compromise

10Background/b73

Epidemiology

›Incidence and exposure patterns

›Acquired methemoglobinemia

›Hospitalized case series report 11% mortality

›Shock at presentation strongest predictor of mortality

›95.5% of patients achieve >=50% MetHb reduction after methylene blue

›Intentional sodium nitrite ingestion

›Emerging trend in self-harm, particularly young adults

›Internet availability of sodium nitrite increases access

›Forensic case series show high lethality without rapid intervention

›Drug-induced cases

›Topical anesthetic-related methemoglobinemia in endoscopy: estimated 1 per 10,000 procedures

›Dapsone-induced cases associated with rebound due to long half-life

›Infant blue baby syndrome

›Linked to well water nitrate contamination in agricultural areas

›~6% of private wells exceed EPA nitrate maximum contaminant level

›Most common in rural regions with intensive agriculture

›Geographic and demographic distribution

›Agricultural regions with fertilizer runoff

›Midwest United States highest prevalence of well water nitrate contamination

›Developing nations with unregulated water supply

›Occupational exposure groups

›Fertilizer manufacturing and agriculture

›Explosives industries

Pathophysiology

›Methemoglobin formation

›Iron oxidation mechanism

›Nitrites oxidize ferrous (Fe2+) to ferric (Fe3+) hemoglobin

›Ferric hemoglobin cannot bind oxygen

›Functional anemia despite normal total hemoglobin

›Left shift of oxyhemoglobin dissociation curve

›Remaining ferrous hemoglobin binds O2 more tightly

›Reduces oxygen unloading to tissues

›Compounding tissue hypoxia beyond simple reduction in O2 carriers

›Physiologic reduction pathway

›Cytochrome b5 reductase reduces MetHb to hemoglobin normally

›Enzymatic capacity exceeded in toxicity

›NADPH-dependent pathway activated by methylene blue

›Vasodilation mechanism

›Nitric oxide generation

›Nitrates converted to nitric oxide in vascular smooth muscle

›Guanylate cyclase activation causes vasodilation

›Venodilation predominates reducing cardiac preload

›Hypotension pathophysiology

›Reduced venous return and cardiac output

›Arterial vasodilation worsens systemic vascular resistance

›Cyanide toxicity from nitroprusside

›Nitroprusside metabolism

›Each molecule releases 5 cyanide ions on degradation

›Cytochrome oxidase inhibition causes histotoxic hypoxia

›Mitochondrial ATP generation blocked

›Lactic acidosis from anaerobic metabolism

Therapeutic Considerations

›Methylene blue mechanism and limitations

›NADPH-dependent reduction

›Methylene blue acts as electron shuttle

›Accelerates MetHb reduction 1000-fold

›Completely dependent on functioning G6PD pathway

›G6PD deficiency implications

›Methylene blue becomes pro-oxidant

›Paradoxically worsens MetHb and causes hemolysis

›Exchange transfusion is definitive treatment

›Serotonin syndrome interaction

›Methylene blue is a monoamine oxidase inhibitor

›Avoid in patients on SSRIs, SNRIs, or other serotonergic agents if possible

›Life-threatening methemoglobinemia overrides this concern

›Evidence base

›2025 AHA Guidelines for CPR and Emergency Cardiovascular Care

›Methylene blue 1-2 mg/kg IV recommended for MetHb-induced hemodynamic instability

›Oxygen adjunct regardless of MetHb level

›2023 AHA Focused Update on Toxicologic Cardiac Arrest

›Exchange transfusion recommended for refractory methemoglobinemia

›Hyperbaric oxygen as rescue therapy

›Pulse oximetry unreliability well established

›Plateaus at 82-87% due to optical properties of MetHb

›Co-oximetry is mandatory for diagnosis and management decisions

11Patient Discharge Instructions/pdi30

copy discharge instructions

›Discharge instruction content

›Diagnosis explanation

›You were treated for nitrate poisoning that caused a blood condition called methemoglobinemia

›Your blood was unable to carry oxygen normally due to chemical changes in hemoglobin

›Treatment with methylene blue helped restore your blood's ability to carry oxygen

›Medications

›Take all prescribed medications as directed

›Avoid the agent that caused your poisoning

›Do not take dapsone, benzocaine sprays, or similar medications without medical guidance

›Activity

›Rest for 24-48 hours after discharge

›Avoid strenuous activity until follow-up

›Follow-up instructions

›Repeat blood methemoglobin level if symptoms recur

›Follow up with your physician within 48-72 hours

›If treated for dapsone-related toxicity, methemoglobin levels can rebound over days

›Water safety

›If your well water was the source, do not use it until tested

›Testing for nitrate and nitrite available through local health departments

›Use alternative water source for infant formula if well water nitrate >10 mg/L

›Return to emergency department immediately for

›Blue, gray, or dark discoloration of lips, fingernails, or skin returning

›Worsening shortness of breath or inability to catch your breath

›Confusion, difficulty thinking clearly, or loss of consciousness

›Chest pain or irregular heartbeat

›Fainting or near-fainting

›Seizures

12References/r32

Guidelines and key sources

›Primary guidelines

›2025 AHA Guidelines for CPR and Emergency Cardiovascular Care Part 10

›Cao D, Arens AM, Chow SL, et al. Circulation 2025

›Methylene blue dosing for methemoglobin-induced hemodynamic instability

›2023 AHA Focused Update on Toxicologic Cardiac Arrest

›Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation 2023

›Exchange transfusion and hyperbaric oxygen for refractory cases

›FDA Drug Label: Methylene Blue Injection

›DailyMed 2024-10-15

›Dosing, contraindications, G6PD warning

Key literature

›Landmark studies and case series

›Davies G et al. Emergency Medicine Journal 2025

›Prehospital methylene blue service for sodium nitrite poisoning

›Novel delivery model for antidote administration

›Tansuwannarat P et al. Clinical Toxicology 2026

›10-year retrospective study of acquired methemoglobinemia

›11% mortality; shock at presentation strongest prognostic factor

›Hickey TBM et al. Forensic Science International 2021

›Fatal methemoglobinemia from intentional sodium nitrite ingestion

›Emerging trend in self-harm

›Chowdhary S et al. JAMA Internal Medicine 2013

›Topical anesthetic-induced methemoglobinemia 10-year case-control study

›Risk quantification for endoscopy procedures

›Kross BC et al. American Family Physician 1992

›Methemoglobinemia nitrate toxicity in rural America

›Well water contamination and infant risk

Evidence & Review

Evidence & Review